Trulieve: The Earnings Beat Is A Mirage, And The Revenue Slide Hasn't Bottomed

Rating: Hold — The Harvest Shuffle Masked A Quarter Worth Watching Closely

Trulieve (NYSE: TRLV) shares jumped 6.6% on Thursday morning after the company reported adjusted earnings per share of $0.11 for Q2 2026, versus a loss of $0.04 a year earlier. The headline beat looked clean enough to headline a story. A closer look shows it was an accounting event dressed up as an operating one — and the stock couldn't hold the advance, giving it all back within hours and falling 4.2% in the session to $8.62.

The question isn't whether Trulieve delivered a beat. The question is whether the medical-only business, now standing on its own for the first time after six months of blending in with the Harvest mixed-use operations, can justify the stock's $1.66 billion market cap. The evidence from this quarter points to a business under pressure, with revenue declining, margins compressing, and cash flow weakening. The stock is cheap, but the cheapness may be earning itself.

What the earnings report actually shows

Trulieve's Q2 revenue of $271 million was down 10% from $302.1 million a year earlier. The GAAP net loss was a staggering $406 million on diluted EPS of -$2.11, versus a consensus EPS estimate of roughly $0.09. That GAAP bomb was almost entirely the Harvest deconsolidation — a $403.3 million loss on separating the mixed-use business, plus $3.3 million from Harvest's equity-method accounting. The Q2 also includes only the first three days of Harvest operations before the June 3 separation, so the revenue number blends two different reporting perimeters.

That $0.11 adjusted EPS beat is the number that moved the stock. Adjusted net income of $20.4 million turned the corner from a $7.7 million loss a year ago, and it's real: it reflects the removal of Section 280E tax penalties on Trulieve's DEA-registered medical operations, combined with disciplined cost management. But the revenue and EBITDA tell a different story. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a cash-proxy measure that strips out non-cash charges and capital structure effects) fell 11% year-over-year to $98 million on a 36% margin, down from $110.6 million at a 37% margin in Q2 2025. Gross profit declined 11% to $162.3 million.

The SG&A number is the red flag. Selling, general, and administrative expenses were $101.8 million, nearly flat from $101.1 million a year ago despite revenue falling 10%. SG&A as a percentage of revenue climbed to 37.6% from 33.5%. Fixed costs don't bend with revenue, which means every dollar of top-line decline flows straight through to EBITDA. That's margin compression with no visible inflection point.

The Harvest deconsolidation: what changed and what it means

On June 3, 2026, Trulieve formally separated its Harvest mixed-use (medical plus adult-use) business from its DEA-registered medical-only operations. The company sold 10% of Harvest's voting stake for approximately $14.8 million to an independent third party, recognizing an estimated $689 million loss in the process, while recording an $188.5 million equity investment. Trulieve retains a 90% economic interest in Harvest and holds an option to reconsolidate if federal rescheduling and NYSE rules allow.

The move was strategic: it was the structural prerequisite for Trulieve to list on the NYSE as the first plant-touching U.S. cannabis company on a major exchange. Trulieve achieved that goal in mid-June, and the institutional-access story is now real rather than aspirational. The medical-only business, with its DEA registrations, is the defensible core. Harvest's adult-use operations — which face ongoing federal prohibition and block Section 280E relief — are now an equity investment rather than a consolidated liability.

But the deconsolidation also removes roughly a third of Trulieve's revenue from the top line. Medical-only revenue in Q2 was $222 million, up 4% sequentially but well below the $271 million blended number. Going forward, medical-only is the reportable business. That's the new baseline to evaluate growth, margins, and valuation.

Cash flow: declining, but still generating

Operating cash flow in Q2 was $53.1 million, down 38% from $86.1 million a year earlier. Free cash flow (operating cash flow less capital expenditures) fell 54% to $32.1 million from $70.1 million. These are meaningful declines.

On the positive side, the full trailing-twelve-month picture is still intact. TTM free cash flow sits at $224.2 million — a 532% year-over-year increase — driven by strong cash generation in the quarters before Harvest separation and the removal of Section 280E drag. The balance sheet is clean: $352.9 million in cash against $289 million in debt, for a net cash position of roughly $247 million. The current ratio is 526%, and debt-to-equity is just 9.2%.

Full-year 2026 operating cash flow guidance was cut to at least $225 million, down from the prior $250 million estimate. Capex guidance was raised to $95 million from $85 million to fund growth in Georgia and Texas. Management sees Q3 revenue at roughly Q2 medical-only levels ($222 million), with Georgia and Pennsylvania offsetting typical summer seasonality in Florida. Gross margins for medical operations are expected to hold at 63%.

Valuation: cheap, but growth has to justify the label

At $8.62, Trulieve trades at a market cap of $1.66 billion and an enterprise value of $1.41 billion. That works out to 4.4x trailing EV/EBITDA and 1.2x EV/sales. On a pure multiple basis, the stock is inexpensive.

The problem is the trajectory. Revenue is down 1.4% year-over-year on a TTM basis and declining sequentially by 2.2%. Adjusted EBITDA is down 11% in the most recent quarter. ROIC is negative at -2.1% and ROE is -6.8%. A 4.4x EV/EBITDA multiple looks cheap for a stable cash-flow generator, but it looks about right for a flat-to-declining revenue business in a competitive market with regulatory overhang.

Trulieve is now comparable to other U.S. MSOs (multi-state operators) trading on alternative venues — Curaleaf on the OTC at roughly $9.46 per share, Cresco Labs at $0.76 — but none of these names have clean public-market comparables with the same depth of analyst coverage. Trulieve's NYSE listing is a structural differentiator, but listing access alone doesn't generate revenue. The stock needs the medical-only business to grow, not just to persist.

Growth levers: Georgia and Texas carry the thesis forward

Georgia is the most compelling near-term catalyst. The state recently removed its THC cap, expanded qualifying conditions, and approved new product formats. Patient enrollment surpassed 45,000, up 38% year-to-date. Traffic tripled in early July, temporarily outpacing supply. Trulieve now supplies nearly 20 independent pharmacies and has triggered eligibility for an eighth dispensary. If Georgia's medical program continues on this trajectory, it provides real scale beyond the Florida base.

Texas is longer-dated but structurally large. Trulieve holds a conditional license for the Texas Compassional Use Program and has completed initial production construction. The program has grown to over 157,000 patients. Management estimates the Florida hemp market (the unregulated intoxicating-hemp competitor) at roughly $4 billion and Texas at $6 billion, versus regulated medical markets of about $2 billion in Florida. If Trulieve can convert even a fraction of that hemp demand into regulated medical sales as state programs mature, the addressable market is substantial.

Federal rescheduling to Schedule III is a backdrop tailwind but not a near-term proof point. It enabled DEA registration and the Section 280E removal that's already flowing through adjusted earnings. Broader legalization — whether throughthe MORE Act or state-level action — remains political speculation.

Risks

• Revenue decline with sticky costs. SG&A is fixed near $100 million per quarter. Until medical-only revenue clears the $240 million threshold, margin compression is the likely path, not expansion.
• Uncertain tax position. Liabilities of $598.2 million on the balance sheet exceed quarter-end cash of $325.4 million. Even with Schedule III relief easing Section 280E, the historical tax bill looms and represents execution risk if the IRS takes an aggressive stance.
• Harvest exposure remains. Trulieve retains 90% economic interest in the mixed-use business it just deconsolidated. If Harvest underperforms, that equity investment — recorded at $188.5 million — could face impairment.
• Insider selling. CEO Kimberly Rivers sold roughly $14.7 million of shares between mid-June and late June, at prices between $8.17 and $9.46. She also net-sold 115,916 shares over the prior six months. Not an automatic bear signal, but worth noting when the stock is already down 27% year-to-date.
• Valuation trap risk. A 4.4x EV/EBITDA multiple looks like a floor, but it's a floor that keeps getting justified by weaker growth. If medical-only revenue plateaus in the $220 million per quarter range, the current multiple isn't a bargain — it's the fair price for flat growth in a cannabis company that still faces federal prohibition.

The investor takeaway

Trulieve's earnings beat was real on the adjusted line, but it was also a product of tax relief from federal rescheduling, not from operational acceleration. Revenue is falling. Margins are compressing. Cash flow is declining on a sequential basis. The Harvest deconsolidation cleaned up the reporting structure and unlocked NYSE access, but it also shrank the top line and removed the adult-use revenue that had been propping up the growth narrative.

The stock is cheap. That much is undeniable at 4.4x EV/EBITDA and 1.2x EV/sales with a net cash balance sheet. But cheap isn't enough when the underlying growth story has stalled and the fixed-cost structure doesn't move down with revenue. The catalysts — Georgia expansion, Texas ramp, federal policy — are all forward-looking with no guarantee of timing or scale.

I'm sitting at Hold. The valuation offers a margin of safety against further downside, but there's no visible inflection point that justifies buying into this quarter's revenue decline. Watch Q3 medical-only revenue: if it holds near $222 million, the flat-growth story remains intact and the current multiple is fair. If Georgia drives medical revenue above $240 million in Q3 or Q4, the margin math flips and the cheap valuation becomes actionable upside. Until then, the earnings beat was a technicality, not a turning point.